[1]马陈※ 帅波※ 沈霖△ 卢芙蓉 杨艳萍 徐晓娟 廖奕.消瘀止血方对迁延期下肢深静脉血栓形成患者非活性菱形蛋白2/解离素金属酶17信号通路表达的影响[J].中国中医骨伤科杂志,2021,29(01):11-14.
　MA Chen SHUAI Bo SHEN Lin LU FurongYANG Yanping XU Xiaojuan LIAO Yi.Effect of Xiaoyu Zhixue Decoction on iRhom2/ADAM17 SignalPathway Expression in Patients with Delayed Lower Extremity DVT[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2021,29(01):11-14.
点击复制

消瘀止血方对迁延期下肢深静脉血栓形成患者非活性菱形蛋白2/解离素金属酶17信号通路表达的影响()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第29卷
期数:
2021年01期
页码:
11-14
栏目:
临床研究
出版日期:
2021-01-15

文章信息/Info

Title:
Effect of Xiaoyu Zhixue Decoction on iRhom2/ADAM17 SignalPathway Expression in Patients with Delayed Lower Extremity DVT
文章编号:
1005-0205(2021)01-0011-04
作者:
马陈1※ 帅波1※ 沈霖1△ 卢芙蓉1 杨艳萍1 徐晓娟1 廖奕1
Author(s):
MA Chen1※ SHUAI Bo1※ SHEN Lin1△ LU Furong1YANG Yanping1 XU Xiaojuan1 LIAO Yi1
1Department of Integrated Traditional Chinese and Western Medicine,Union Hospital Affiliated to Tongji MedicalCollege of Huazhong University of Science and Technology,Wuhan 430022,China.
关键词:
下肢静脉血栓形成;  非活性菱形蛋白2;  解离素金属酶17;  消瘀止血方;  血小板黏附
Keywords:
lower extremity deep venous thrombosis;  inactive rhomboid-like protein 2;  disintegrin and metalloprotease 17;  Xiaoyu Zhixue decoction;  platelet adhesion
分类号:
R543.6
文献标志码:
A
摘要:
目的:研究迁延期下肢深静脉血栓患者非活性菱形蛋白2(iRhom2)/解离素金属酶17(ADAM17)信号通路相关分子的表达变化及消瘀止血方的疗效及作用机制。方法:67例迁延期下肢静脉血栓患者均服用消瘀止血方,另选健康体检者50人作为正常对照组,治疗周期均为60 d。观察治疗前后症状、体征变化,彩色多普勒检查股静脉、腘静脉及小腿静脉丛再通情况。采用Western Blot法检测患者治疗前后及正常对照组的iRhom2/ADAM17信号通路相关分子蛋白表达水平。结果:迁延期下肢深静脉血栓形成患者iRhom2,ADAM17蛋白表达水平明显高于正常组(P<0.01); pro-ADAM17与正常组比较差异无统计学意义(P>0.05)。消瘀止血方治疗60 d后,患者疼痛、皮肤色泽、肿胀及浅静脉怒张均有明显改善; iRhom2及ADAM17蛋白表达明显下降,与治疗前比较差异有统计学意义(P<0.01)。结论:促炎信号通路iRhom2/ADAM17参入了迁延期下肢深静脉血栓形成的病理过程; 消瘀止血方治疗迁延期下肢深静脉血栓形成的疗效机理之一,可能是通过调节iRhom2/ADAM17信号通路异常表达,降低患者血小板黏附功能这一关键靶点而实现的。
Abstract:
To study the expression changes of iRhom2/ADAM17 signal pathway related molecules in patients with delayed deep venous thrombosis(DVT)of lower extremity and the efficacy and mechanism of Xiaoyu Zhixue decoction.Methods:67 patients with delayed lower extremity DVT were treated with Xiaoyu Zhixue decoction,and 50 healthy persons were selected as normal control group.The treatment cycle was 60 d.The changes of symptoms and signs were observed before and after treatment,and the recanalization of femoral vein,popliteal vein and calf venous plexus were examined by color Doppler.Western Blot method was used to detect the expression of iRhom2/ADAM17 signal pathway related molecular proteins in patients before and after treatment and in normal control group.Results:The expression levels of iRhom2 and ADAM17 protein in patients with delayed lower extremity DVT were significantly higher than those in normal group(P<0.01); there was no significant difference of pro-ADAM17 compared with normal group(P>0.05).After 60 d of Xiaoyu Zhixue decoction treatment,the pain,skin color,swelling and superficial vein engorgement of patients were significantly improved; the expression of iRhom2 and ADAM17 protein were significantly decreased,and the differences were statistically significant(P<0.01).Conclusion:The inflammatory signal pathway iRhom2/ADAM17 is involved in the pathological process of delayed lower extremity DVT; one of the therapeutic mechanisms of Xiaoyu Zhixue decoction in treating delayed DVT of lower extremity may be achieved through regulating the abnormal expression of iRhom2/ADAM17 signal pathway and inhibiting platelet adhesion function.

参考文献/References:

[1] 凌家艳,沈霖,刘庆.消瘀止血方治疗下肢深静脉血栓形成慢性期临床观察[J].中国中医骨伤科杂志,2013,21(10):42-43.
[2] XU M X,GE C X,QIN Y T,et al.Multicombination approach suppresses listeria monocytogenes-induced septicemia-associated acute hepatic failure:the role of iRhom2 signaling[J].Adv Healthc Mater,2018,7(17):e1800427.
[3] BADENES M,ADRAIN C.iRhom2 and TNF:partners or enemies?[J] Sci Signal,2019,12(605):eaaz 0444.
[4] 中国中西医结合学会周围血管疾病专业委员会.下肢深静脉血栓形成诊断及疗效标准(2015年修订稿)[J].中国中西医结合外科学杂志,2016,22(5):520-521.
[5] 中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南[J].中国血管外科杂志(电子版),2017,19(4):250-257.
[6] 付赢,李义,郎彦波,等.脉炎宁颗粒治疗下肢深静脉血栓形成迁延期疗效观察[J].山西中医,2016,32(7):21-24.
[7] 回雪颖,郭伟光,滕林,等.下肢深静脉血栓形成的中医研究进展[J].中医药学报,2020,48(5):66-69.
[8] DUSTERHOFT J S,BABENDREYER A,GIESE A A,et al.Status update on iRhom and ADAM17:it’s still complicated[J]. Biochim Biophys Acta Mol Cell Res,2019,1866(10):1567-1583.
[9] CAVADAS M,OIKONOMIDI I,GASPAR C J,et al.Phosphorylation of iRhom2 controls stimulated proteolytic shedding by the metalloprotease ADAM17/TACE[J].Cell Rep,2017,21(3):745-757.
[10] MATTHEWS A L,NOY P J,REYAT J S,et al.Regulation of A disintegrin and metalloproteinase(ADAM)family sheddases ADAM10 and ADAM17:the emerging role of tetraspanins and rhomboids[J].Platelets,2017,28(4):333-341.
[11] DOBIE G,KURIRI F A,OMAR M,et al.Ibrutinib,but not zanubrutinib,induces platelet receptor shedding of GPIb-Ⅳ-Ⅴ complex and integrin αⅡbβ3 in mice and humans[J].Blood Adv,2019,3(24):4298-4311.
[12] JANDROT-PERRUS M,HERMANS C,MEZZANO D.Platelet glycoprotein Ⅵ genetic quantitative and qualitative defects[J].Platelets,2019,30(6):708-713.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81673761,81974546,82004201)
1华中科技大学同济医学院附属协和医院中西医结合科(武汉,430022)※同等贡献,并列第一作者
△通信作者 E-mail:shenlinhb@sina.cn
更新日期/Last Update: 2021-01-15